Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pyridostigmine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Pyridostigmine. Displaying page 1 of 1.
    EudraCT Number: 2009-010758-36 Sponsor Protocol Number: WC2008-106 Start Date*: 2009-05-19
    Sponsor Name:VU University Medical Center
    Full Title: Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1
    Medical condition: Patients with CRPS-1.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004110-20 Sponsor Protocol Number: 78666 Start Date*: 2022-10-12
    Sponsor Name:Leiden University Medical Center
    Full Title: Improving symptomatic treatment with pyridostigmine and amifampridine: a randomized double-blinded, placebo controlled crossover trial in patients with myasthenia gravis (IMPACT-MG)
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004852 10085562 AChR myasthenia gravis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002599-15 Sponsor Protocol Number: 21709298 Start Date*: 2017-11-07
    Sponsor Name:Aarhus University
    Full Title: Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis.
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10071942 Myasthenia gravis and related conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004723-17 Sponsor Protocol Number: UZBSK001 Start Date*: 2021-02-26
    Sponsor Name:UZ Brussel
    Full Title: Clinical usefulness and influence on oesophageal motility of pyridostigmine for dysphagia in systemic sclerosis.
    Medical condition: Dysphagia by patients suffering from systemic sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004369-34 Sponsor Protocol Number: UMC-NMZ-SMA2011 Start Date*: 2015-04-22
    Sponsor Name:Universtiy Medical Center Utrecht
    Full Title: SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients ...
    Medical condition: Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10068209 Spinal muscular atrophy adult onset LLT
    17.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001355-23 Sponsor Protocol Number: 40960 Start Date*: 2014-08-29
    Sponsor Name:Leiden University Medical Center
    Full Title: Ephedrine as add-on therapy for patients with myasthenia gravis
    Medical condition: myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000122-21 Sponsor Protocol Number: SJ-193 Start Date*: 2012-08-10
    Sponsor Name:Department of Neurology, Roskilde Hospital
    Full Title: Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease
    Medical condition: Ortostatic hypotension in patients with Parkinsons disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10031127 Orthostatic hypotension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003997-18 Sponsor Protocol Number: GTI1408 Start Date*: 2015-07-07
    Sponsor Name:Grifols Therapeutics Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (IGIV -C) in Symptomatic Su...
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000323-27 Sponsor Protocol Number: CV-0003 Start Date*: 2017-08-03
    Sponsor Name:CuraVac Europe SA
    Full Title: A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG0...
    Medical condition: Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is a decrease in the number of available acetylcho...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002610-14 Sponsor Protocol Number: 79835 Start Date*: 2021-09-08
    Sponsor Name:Aarhus University Hospital, Department of Neurology
    Full Title: Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study.
    Medical condition: Post-COVID-19 Myopathy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10062913 Muscle weakness conditions HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002068-26 Sponsor Protocol Number: BEL115123 Start Date*: 2011-11-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG).
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004018-25 Sponsor Protocol Number: MSK-002 Start Date*: 2018-02-22
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Pos...
    Medical condition: MuSK antibody positive myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000358-23 Sponsor Protocol Number: CMS-001 Start Date*: 2019-02-06
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: A phase 3, multicenter, double-blind, placebo-controlled, randomized, outpatient two-period two-treatment crossover study to evaluate the efficacy and safety of amifampridine phosphate (3,4 diamino...
    Medical condition: Congenital myasthenic syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028424 Myasthenic syndrome PT
    20.0 10029205 - Nervous system disorders 10028425 Myasthenic syndromes in diseases classified elsewhere LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021850-20 Sponsor Protocol Number: LMS-002 Start Date*: 2011-09-26
    Sponsor Name:Catalyst Pharmaceutical Partners, Inc.
    Full Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (...
    Medical condition: Lambert-Eaton Myasthenic Syndrome (LEMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10067685 Lambert-Eaton myasthenic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) CZ (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date*: 2005-05-19
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028417 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 13:50:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA